Contraception in Women With Medical Comorbidities: Clinical Risk Stratification and Individualized Therapeutic Strategies
Abstract
Women of reproductive age increasingly present with chronic medical conditions that significantly influence contraceptive safety and effectiveness. Hormonal contraceptives, particularly estrogen-containing formulations, exert systemic effects on coagulation pathways, vascular tone, blood pressure regulation, and metabolic function. These mechanisms contribute to an increased risk of venous thromboembolism, hypertension, and cardiovascular events in susceptible populations, especially in women with obesity, diabetes mellitus, dyslipidemia, autoimmune disorders, or pre-existing cardiovascular disease. Progestin-only methods generally demonstrate a lower thrombotic risk profile; however, their metabolic and systemic effects vary depending on the specific formulation. Long-acting reversible contraceptives, including levonorgestrel-releasing and copper intrauterine devices, offer highly effective options with minimal systemic impact and are frequently recommended for women with contraindications to estrogen. Comorbid conditions such as systemic lupus erythematosus, antiphospholipid syndrome, chronic liver disease, chronic kidney disease, and hormone-sensitive malignancies further complicate contraceptive decision-making. In these settings, individualized risk assessment must consider organ-specific vulnerability, disease activity, and potential drug-drug interactions, particularly with enzyme-inducing medications or immunosuppressive therapies. Evidence-based eligibility…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.